[HTML][HTML] Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies
SA Luebker, SA Koepsell - Frontiers in oncology, 2019 - frontiersin.org
BRAF inhibitor therapy may provide profound initial tumor regression in metastatic
melanoma with BRAF V600 mutations, but treatment resistance often leads to disease …
melanoma with BRAF V600 mutations, but treatment resistance often leads to disease …
[HTML][HTML] Mechanisms of acquired BRAF inhibitor resistance in melanoma: a systematic review
I Proietti, N Skroza, N Bernardini, E Tolino, V Balduzzi… - Cancers, 2020 - mdpi.com
Simple Summary Patients with advanced melanoma are often treated with v-raf murine
sarcoma viral oncogene homolog B1 (BRAF) inhibitors. Although these agents prolong life …
sarcoma viral oncogene homolog B1 (BRAF) inhibitors. Although these agents prolong life …
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact
Purpose: Multiple BRAF inhibitor resistance mechanisms have been described, however,
their relative frequency, clinical correlates, and effect on subsequent therapy have not been …
their relative frequency, clinical correlates, and effect on subsequent therapy have not been …
[HTML][HTML] Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
GV Long, C Fung, AM Menzies, GM Pupo… - Nature …, 2014 - nature.com
One-third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and
MEK inhibition progress within 6 months. Treatment options for these patients remain …
MEK inhibition progress within 6 months. Treatment options for these patients remain …
[HTML][HTML] Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB
Monoclonal antibodies against immune checkpoint blockade have proven to be a major
success in the treatment of melanoma. The programmed death receptor-1 ligand-1 (PD-L1) …
success in the treatment of melanoma. The programmed death receptor-1 ligand-1 (PD-L1) …
[HTML][HTML] Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Abstract Treatment of BRAF-mutant metastatic melanoma with mitogen-activated protein
kinase (MAPK) pathway targeted therapies (BRAF/MEK inhibitors) and immune checkpoint …
kinase (MAPK) pathway targeted therapies (BRAF/MEK inhibitors) and immune checkpoint …
[HTML][HTML] Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis
The incidence of melanoma is increasing over the years with a still poor prognosis and the
lack of a cure able to guarantee an adequate survival of patients. Although the new immuno …
lack of a cure able to guarantee an adequate survival of patients. Although the new immuno …
[HTML][HTML] Mechanisms of immunotherapy resistance in cutaneous melanoma: recognizing a shapeshifter
Melanoma is one of the seven most common cancers in the United States, and its incidence
is still increasing. Since 2011, developments in targeted therapies and immunotherapies …
is still increasing. Since 2011, developments in targeted therapies and immunotherapies …
Potential therapeutic targets of epithelial–mesenchymal transition in melanoma
RL Pearlman, MKM de Oca, HC Pal, F Afaq - Cancer letters, 2017 - Elsevier
Melanoma is a cutaneous neoplastic growth of melanocytes with great potential to invade
and metastasize, especially when not treated early and effectively. Epithelial-mesenchymal …
and metastasize, especially when not treated early and effectively. Epithelial-mesenchymal …
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
CD Britten - Cancer chemotherapy and pharmacology, 2013 - Springer
Abstract The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are two of the most
frequently dysregulated kinase cascades in human cancer. Molecular alterations in these …
frequently dysregulated kinase cascades in human cancer. Molecular alterations in these …